SPRED2 Double Nickase Plasmid (h): sc-404738-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SPRED2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- SPRED2 Double Nickase Plasmid (h) and SPRED2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting SPRED2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SPRED2 Antibody (6G8): sc-517018
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SPRED2 Double Nickase Plasmid (h) | sc-404738-NIC | 20 µg | $410.00 | |||
SPRED2 Double Nickase Plasmid (h2) | sc-404738-NIC-2 | 20 µg | $410.00 |
SPRED2 (Sprouty related EVH1 domain containing 2) is a cytosolic adaptor protein that functions as a negative regulator of receptor tyrosine kinase signaling by restraining RAF/MEK/ERK (MAPK) pathway activation. By interacting with components such as RAF and modulating RAS-dependent signaling complexes, SPRED2 helps control growth factor–driven proliferation, differentiation, and inflammatory responses. Altered SPRED2 expression or function has been associated with dysregulated MAPK signaling programs implicated across cancer biology and immune-mediated processes, supporting its utility as a node for studying signal attenuation and feedback control. In human cells, SPRED2 perturbation provides a tractable approach to interrogate pathway crosstalk between MAPK signaling and downstream transcriptional and cytoskeletal outputs.
SPRED2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the SPRED2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within SPRED2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt SPRED2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of SPRED2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.